List view / Grid view
In this Q&A, Dr Frank Neumann speaks about Kite Pharma’s work with chimeric antigen receptor (CAR) T-cell therapy and how the company is working to progress this next‑generation modality even further to help treat cancer patients.
In this Q&A, Dr Devon Shedlock discusses Poseida Therapeutics' cancer treatment pipeline and the advances it has made towards developing chimeric antigen receptor (CAR) T-cell therapies for liquid and solid tumours.
Drug Target Review’s Izzy Wood spoke to Joseph Hernandez, CEO of Blue Water Vaccines, about developing transformational vaccines to address significant health challenges globally.
In this article, Dr Daniel Teper and Dr Chris Arendt explore cellular therapies for cancer that provide an alternative to chimeric antigen receptor (CAR) T-cell therapy. In these Q&As, they outline their important work in immuno-oncology.
Here, Dr Michael Leek describes the benefits of gamma-delta T cells for cancer therapy, exploring why they present a potential alternative to other immuno-oncology platforms.
Researchers from the University of Pennsylvania have developed a novel organ-on-a-chip technology called OCTOPUS, an optimised device for growing mini-organs in a dish.
In this article, Drug Target Review’s Izzy Wood reviews some of the latest Alzheimer's disease research, highlighting the progress that has been made toward new, more unique therapeutic strategies against Alzheimer’s.
Using flow cytometry, Dr Greg Delgoffe and Dr Paolo Vignali highlight that low oxygen environment of tumours can prompt exhausted T cells to suppress the immune system instead of combating cancer.
As COVID-19 continues to evolve, researchers are still on the lookout for new ways to protect against the virus. Drug Target Review brings you some of the most recent pre-clinical developments.
This article highlights five of the latest findings using cell and gene therapy techniques that could be used in the development or design of new therapies.
This exclusive interview highlights some of Dr Arthur Suckow’s insights into how his team uses RNA therapies to treat rare diseases such as Charcot-Marie-Tooth 1A.
Drug Target Review’s Ria Kakkad recently spoke with Dr Jane Osbourn about her experience as a woman in STEM.
Dr Douglas Ross-Thriepland and Dr David Walter, from the Functional Genomics Centre (FGC) – a joint venture between Cancer Research UK’s (CRUK) drug discovery engine, Cancer Research Horizons, and AstraZeneca – speak to Drug Target Review about their work. The centre’s focus is on genetic screening; cancer models; CRISPR reagent…
An autonomous strategy for molecular discovery could enable the exploration of a far broader chemical space than is possible with conventional approaches. In this article, Niamh Morris from Rosalind Franklin Institute outlines why activity-directed synthesis (ADS) could be the answer, providing examples of how this technique has the potential to…
Dr Sheraz Gul examines how patient-driven imaging strategies can be utilised to aid the translation of initial research all the way into the clinic.
